Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DHR
stocks logo

DHR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
6.79B
+3.78%
2.138
-0.08%
5.99B
+4.33%
1.996
+6.18%
6.16B
+3.75%
1.964
+9.13%
Estimates Revision
The market is revising Downward the revenue expectations for Danaher Corporation (DHR) for FY2025, with the revenue forecasts being adjusted by -0.75% over the past three months. During the same period, the stock price has changed by 14.12%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.75%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.73%
In Past 3 Month
Stock Price
Go Up
up Image
+14.12%
In Past 3 Month
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 243.45 USD with a low forecast of 220.00 USD and a high forecast of 260.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 243.45 USD with a low forecast of 220.00 USD and a high forecast of 260.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
3 Hold
0 Sell
Strong Buy
Current: 227.130
sliders
Low
220.00
Averages
243.45
High
260.00
Current: 227.130
sliders
Low
220.00
Averages
243.45
High
260.00
Wells Fargo
Equal Weight
maintain
$205 -> $230
2025-10-23
Reason
Wells Fargo
Price Target
$205 -> $230
2025-10-23
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Danaher to $230 from $205 and keeps an Equal Weight rating on the shares. The firm notes the company reaffirmed its 2025 EPS guide, despite lowering Q4 organic growth. Initial 2026 outlook calls for positive high single digit EPS growth, even at low-end of +3%-6% core revenue growth, which seems to leave room for upside on Life Sci, OP margin and capital allocation fronts.
TD Cowen
Buy
upgrade
$250 -> $260
2025-10-22
Reason
TD Cowen
Price Target
$250 -> $260
2025-10-22
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Danaher to $260 from $250 and keeps a Buy rating on the shares. The firm updated its model following Q3 results and said accelerated cost cuts into what could be an easier recovery in 2026 offered a clearing event for believers in the company's bioprocess-driven story despite a mixed print/guide.
Baird
NULL
to
Outperform
maintain
$236 -> $247
2025-10-22
Reason
Baird
Price Target
$236 -> $247
2025-10-22
maintain
NULL
to
Outperform
Reason
Baird raised the firm's price target on Danaher to $247 from $236 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
BofA
analyst
Buy
downgrade
$230 -> $220
2025-09-22
Reason
BofA
analyst
Price Target
$230 -> $220
2025-09-22
downgrade
Buy
Reason
BofA lowered the firm's price target on Danaher to $220 from $230 and keeps a Buy rating on the shares. While there has been some stabilization and/or improvement in some areas of Life Sciences and Diagnostic Tools, several pockets of uncertainty and softness over the past year remain and are likely to persist for at least the next few quarters, says the analyst, who is trimming forecasts for many core Tools companies and now anticipates a more gradual return to "normal."
RBC Capital
Outperform
maintain
$250 -> $241
2025-09-02
Reason
RBC Capital
Price Target
$250 -> $241
2025-09-02
maintain
Outperform
Reason
RBC Capital lowered the firm's price target on Danaher to $241 from $250 and keeps an Outperform rating on the shares as part of a broader research note on the Life Sciences Tools and Diagnostics sector. The firm is updating its model with "more realistic" multiples, the analyst tells investors in a research note. September isn't a great month to own healthcare, and with a rebound still 2-3 quarters away, this isn't the time to broadly own the sector, RBC added.
Wells Fargo
Equal Weight
maintain
$210 -> $205
2025-07-23
Reason
Wells Fargo
Price Target
$210 -> $205
2025-07-23
maintain
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Danaher to $205 from $210 and keeps an Equal Weight rating on the shares. The firm notes the company posted a solid beat/raise on EPS, while also leaving another about +15c-20c in its back pocket. Bioprocess continues to show a solid recovery, while LS should improve in the second half of the year. Pharma and China commentary was positive, Wells adds, arguing that CFO transition seems manageable.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Danaher Corp (DHR.N) is 28.21, compared to its 5-year average forward P/E of 28.66. For a more detailed relative valuation and DCF analysis to assess Danaher Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
28.66
Current PE
28.21
Overvalued PE
32.05
Undervalued PE
25.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
22.51
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
24.99
Undervalued EV/EBITDA
20.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.67
Current PS
0.00
Overvalued PS
7.45
Undervalued PS
5.89
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased306.25%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

DHR News & Events

Events Timeline

(ET)
2025-12-01
16:40:00
Morgan Stanley Initiates Coverage on Veracyte with Underweight Rating, Price Target at $48
select
2025-12-01
16:40:00
Morgan Stanley Assigns Overweight Rating to Thermo Fisher with $670 Price Target
select
2025-12-01
16:40:00
Morgan Stanley Initiates Coverage on Natera with Overweight Rating, Price Target Raised to $265
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
12-04Yahoo Finance
Jim Cramer: "Danaher Has Shown Significant Improvement"

  • Danaher Corporation Overview: Jim Cramer continues to support Danaher Corporation (NYSE: DHR) for the Charitable Trust, highlighting its recent focus on life sciences diagnostics after spinning off its water and product quality testing business.

  • Recent Performance: The stock has seen a significant recovery, rising 31% from its April low and 25% from its September low, driven by strong growth in its bioprocessing division and a recent earnings beat.

  • Future Expectations: Analysts anticipate that Danaher will achieve its best growth in years by 2026, with expectations of mid-single-digit revenue growth and high single-digit earnings growth.

  • Investment Considerations: While Danaher shows potential, the article suggests that certain AI stocks may offer better upside potential and lower downside risk, encouraging readers to explore undervalued AI investment opportunities.

[object Object]
Preview
5.0
12-04Yahoo Finance
Brady Corporation Appoints Board of Directors and Announces Regular Dividend for Shareholders

  • Shareholder Vote: Brady Corporation's Class B Common Voting Stock shareholders unanimously elected a new Board of Directors during the annual meeting held in Milwaukee on December 3, 2025.

  • New Board Members: The newly elected directors include experienced professionals from various industries, such as Patrick W. Allender, Dr. David S. Bem, and Joanne Collins Smee, among others.

  • Dividend Declaration: The Board declared a dividend of $0.245 per share for Class A Common Stock, set to be paid on January 30, 2026, to shareholders of record by January 9, 2026.

  • Company Overview: Founded in 1914 and headquartered in Milwaukee, Brady Corporation specializes in safety and identification solutions, employing approximately 6,400 people and reporting fiscal 2025 sales of about $1.51 billion.

[object Object]
Preview
3.0
12-04NASDAQ.COM
DHR Stock Analysis Using Factor-Based Approach - Martin Zweig

  • DANAHER CORP Overview: DANAHER CORP (DHR) is rated highly by Validea's Growth Investor model, achieving a score of 54% based on its fundamentals and valuation, indicating moderate interest in the stock.

  • Growth Investor Strategy: The strategy focuses on identifying growth stocks with consistent earnings and sales growth, reasonable valuations, and low debt, with scores above 80% suggesting stronger interest.

  • Martin Zweig's Background: Martin Zweig, whose strategy is used in the analysis, had a successful investment newsletter with an average annual return of 15.9% over 15 years and is known for his significant wealth and unique collectibles.

  • Validea's Research Service: Validea provides investment research based on the strategies of renowned investors, offering stock analysis and model portfolios aimed at long-term market outperformance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Danaher Corp (DHR) stock price today?

The current price of DHR is 227.13 USD — it has decreased -0.58 % in the last trading day.

arrow icon

What is Danaher Corp (DHR)'s business?

Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

arrow icon

What is the price predicton of DHR Stock?

Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 243.45 USD with a low forecast of 220.00 USD and a high forecast of 260.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Danaher Corp (DHR)'s revenue for the last quarter?

Danaher Corp revenue for the last quarter amounts to 6.05B USD, increased 4.40 % YoY.

arrow icon

What is Danaher Corp (DHR)'s earnings per share (EPS) for the last quarter?

Danaher Corp. EPS for the last quarter amounts to 1.27 USD, increased 13.39 % YoY.

arrow icon

What changes have occurred in the market's expectations for Danaher Corp (DHR)'s fundamentals?

The market is revising Downward the revenue expectations for Danaher Corporation (DHR) for FY2025, with the revenue forecasts being adjusted by -0.75% over the past three months. During the same period, the stock price has changed by 14.12%.
arrow icon

How many employees does Danaher Corp (DHR). have?

Danaher Corp (DHR) has 61000 emplpoyees as of December 05 2025.

arrow icon

What is Danaher Corp (DHR) market cap?

Today DHR has the market capitalization of 160.43B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free